Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

West Syndrome Market is Projected to Rising at a Steady Growth at a 5.8% CAGR During the Study Period [2018-2030], Analyses DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

14 Jul, 2021, 16:30 GMT

Share this article

Share toX

Share this article

Share toX

The upcoming therapies, Epidiolex by GW Pharmaceuticals and JBPOS0101 by BioPharm Solutions, are anticipated to generate a decent West Syndrome market revenue in the forecast period of 2021-2030. 

LAS VEGAS, July 14, 2021 /PRNewswire/ -- DelveInsight's "West Syndrome Market" report provides a thorough comprehension of the West Syndrome historical and forecasted epidemiology and the West Syndrome market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The West Syndrome market report also proffers an analysis of the current West Syndrome treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

 Some of the necessary takeaways from the West Syndrome Market Research Report  

  • Epidiolex has been granted Orphan Drug Designation for the treatment of West Syndrome patients by the US FDA.
  • The Cannabidiol therapies by BioPharm Solutions and GW Pharma, once approved, will drive the West Syndrome market revenue. 
  • West Syndrome Market will boom due to companies' clinical development activities, product innovations, and technological advancements. There is support from various organizations to increase awareness of the disease. Also, a growing number of births and rising West Syndrome prevalence is observed. 
  • The factors such as delayed diagnosis and treatment, serious side effects of medications, lack of prevalence-based studies, challenges in conducting clinical trials, and lack of late phase clinical studies will hamper the West Syndrome Market growth. 
  • Several key pharmaceutical companies include Lundbeck, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, GW Pharmaceuticals, BioPharm Solutions, and others, are developing novel products to improve the West Syndrome treatment outlook. 
  • Apart from these, various other companies such as Catalyst Pharmaceuticals and Avanex Life Sciences Corporation are exploring their therapeutics for infantile spasms in the early stages of clinical development.
  • Looking at the historical trend of emerging therapies, their probability of success in entering the West Syndrome market remains a bit low, considering that key Epilepsy players such as Marinus Pharma and Insys therapeutics did not continue developing their respective drugs owing to unsatisfactory responses. Later, Insys therapeutics winded down its operations. 

For further information on Market Impact by Therapies, visit: West Syndrome Drugs Market Analysis 

West Syndrome is an age-related specific epileptic encephalopathy due to multiple and diverse causes. It is characterized by a unique type of seizure called epileptic (infantile) spasms and gross EEG abnormalities of hypsarrhythmia. 

DelveInsight estimates that the total diagnosed West Syndrome prevalent population in the 7MM was 8,601 cases in 2020. Moreover, West Syndrome is more prevalent in males than in females. 

The West Syndrome Market Analysis Report provides historical as well as forecasted epidemiological analysis segmented into: 

  • Total West Syndrome Prevalent Population 
  • Total Diagnosed Prevalent Population of West Syndrome
  • Gender-specific Diagnosed West Syndrome Prevalent Population 

Get a complete epidemiological segmentation analysis @ West Syndrome Epidemiological Analysis 

West Syndrome Treatment Market 

The current treatment of West Syndrome involves Hormonal Therapy (ACTH), Vigabatrin, Corticosteroids, and other off-label therapies, among the most common medications used as a first-line treatment option. On the other hand, Anti-epileptic Drugs (AEDs) form the second-line treatment for West Syndrome patients. ACTH (Adrenocorticotropic hormone) is probably the most universally accepted first-line treatment and the most effective in treating West Syndrome. 

Along with ACTH, corticosteroids are also usually the first line of treatment options for the disease. Prednisolone is appealing because of its low cost, ready accessibility in many countries, ease of administration, and increasing evidence that it may be similar in efficacy to ACTH and vigabatrin. 

West Syndrome Marketed & Emerging Drugs 

There are two approved products, namely Sabril (vigabatrin) and Acthar Gel (corticotropin injection), to treat  the West Syndrome. Out of these two therapies, vigabatrin is approved in the US, Europe, and Japan; however, Acthar Gel is only approved in the US and is used as off-label therapy in the other two regions. In addition, in Europe, vigabatrin is marketed by Orphelia Pharma by the brand name Kigabeq. 

The current West Syndrome emerging market lacks a robust pipeline with GW Pharma and BioPharm Solutions as major players, Epidiolex (GW Pharmaceuticals) is in its phase III developmental stage, whereas BioPharm Solutions is conducting a phase II clinical developmental trial for its antiepileptic drug candidate JBPOS0101, but the results of this trial have not been published yet. 

To conclude, the West Syndrome Market growth will enlarge since many companies are innovating. The technological advancements will help in better diagnosis and treatment, thereby resulting in a lucrative market opportunity. The current treatment options are very few for treating patients with West syndrome, which opens a platform of new therapies to enter the market. The key West Syndrome pipeline therapies are expected to get launched in the market as early as possible, hold several partnerships and collaborations, and designations from the FDA. 

Nevertheless, the growth of the West Syndrome Market might be hindered due to the lack of awareness of indication among healthcare providers, which results in delays in diagnosis and treatment. There are only two approved therapies to date to treat West syndrome (vigabatrin and corticotropin injection), which also have adverse side effects. In addition, various issues are faced while conducting West Syndrome clinical trials, impacting the actual analysis. There is a lack of late-phase clinical studies, which means not many therapies will be approved anytime soon.

Scope of the West Syndrome Market Insight Report  

  • Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 
  • Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
  • West Syndrome Markets Segmentation: By Geographies and By West Syndrome Therapies (Historical and Forecasted, Current and Upcoming) 
  • Dominant Market Companies investigating its candidates for West Syndrome: Lundbeck, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, GW Pharmaceuticals, BioPharm Solutions, and several others. 
  • Analysis: Comparative and conjoint analysis of emerging therapies. 
  • Case Studies
  • KOL's Views
  • Analyst's View

Request for a Webex demo of the report @ West Syndrome Therapeutics Market

Table of Contents 

1

West Syndrome Key Insights

2

West Syndrome Market Overview at a Glance

3

Executive Summary of West Syndrome 

4

West Syndrome Disease Background and Overview 

5

Diagnostic Algorithm for West Syndrome

6

Clinical Algorithm for Epileptic Spasms (Infantile Spasms) By Texas Children's Hospital

7

Epidemiology and Patient Population

7.1

The United States

7.2

EU5 Countries

7.2.1

Germany

7.2.2

France

7.2.3

Italy

7.2.4

Spain

7.2.5

The United Kingdom

7.3

Japan

8

 West Syndrome Treatment

9

 West Syndrome Treatment Algorithm 

10

Guidelines for the Management and Treatment of Infantile Seizures

11

West Syndrome Marketed Products

11.1

Sabril (Vigabatrin): Lundbeck

11.2

H.P. Acthar Gel: Questcor Pharmaceuticals/Mallinckrodt Pharmaceuticals

12

West Syndrome Emerging Therapies

12.1

Epidiolex (GWP42003-P): GW Pharmaceuticals

12.2

JBPOS0101: BioPharm Solutions

13

West Syndrome 7MM Market Analysis

13.1

The United States West Syndrome Market Size

13.2

EU-5 West Syndrome Market Size

13.2.1

Germany Market Size

13.2.2

France Market Size

13.2.3

Italy Market Size

13.2.4

Spain Market Size

13.2.5

The United Kingdom Market Size

13.2.3

Japan West Syndrome Market Size

14

Case Reports

15

Recognized Establishments

16

West Syndrome Unmet Needs

17

West Syndrome Market Drivers

18

West Syndrome Market Barriers

19

SWOT Analysis of West Syndrome                      

20

Appendix

21

DelveInsight Capabilities

22

Disclaimer

23

About DelveInsight

Browse full report with detailed TOC with charts, figures, tables @ West Syndrome Diagnostics Market Report

View Other Reports

  • West Syndrome Epidemiology 

DelveInsight's 'West Syndrome - Epidemiology Forecast–2030' report delivers an in-depth understanding of the disease, historical and forecasted West Syndrome epidemiology in 7MM.

  • Polymyalgia Rheumatica Market 

Polymyalgia Rheumatica Market Size, Share | Polymyalgia Rheumatica Market Research Report. Key players are Roche, Chugai, Bristol-Myers Squibb,  Eli Lilly, and others. 

  • Exocrine Pancreatic Insufficiency (EPI) Market 

DelveInsight's Exocrine Pancreatic Insufficiency Market Insights, Epidemiology & Forecast 2030 report gives an overview of disease & understanding of historical and forecasted epidemiology. Key players are AbbVie, Nestle, AzurRx BioPharma, and others. 

  • EGFR Inhibitors-Induced Skin Disorders Market 

DelveInsight's EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. Key players are AstraZeneca, Pfizer, Novartis Pharmaceuticals, Janssen Research & Development, Yuhan Corporation, Takeda, and others.

  • Adult Myopia Market 

DelveInsight's Adult Myopia Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Key players are Genentech, Bayer AG, and others. 

  • Malignant Pleural Mesothelioma Market

DelveInsight's Malignant Pleural Mesothelioma (MPM) - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and in historical and forecasted West Syndrome epidemiology in 7MM.

  • Meningioma Market 

DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Meningioma, historical and forecasted epidemiology.

  • Meniscus Tear Market 

DelveInsight's Meniscus Tear Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

  • Metastatic Bone Cancer Market 

DelveInsight's Metastatic Bone Cancer Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

Browse Blog Posts

  • Diabetic Macular Edema Therapy Market to Witness Significant Impact in the Foreseeable Future
  • What Factors are Shaping the Trends in the Implantable Cardiac Monitors Market?

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach. 

Contact Us:

Shruti Thakur
info@delveinsight.com   
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg  

Modal title

Also from this source

Global Pharmaceutical Contract Manufacturing Market to Surpass the USD 360 Billion Mark by 2032 | DelveInsight

Global Pharmaceutical Contract Manufacturing Market to Surpass the USD 360 Billion Mark by 2032 | DelveInsight

DelveInsight's Pharmaceutical Contract Manufacturing Market Insights report provides the current and forecast market analysis, individual leading...

GSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsight

GSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsight

DelveInsight's GSK 3 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding ...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.